Tags

Type your tag names separated by a space and hit enter

Photosensitizer delivery for photodynamic therapy of choroidal neovascularization.
Adv Drug Deliv Rev. 2001 Oct 31; 52(1):63-78.AD

Abstract

The present review examines the importance of improving photosensitizer delivery for choroidal neovascularization (CNV) in light of the clinical impact of photodynamic therapy (PDT) for CNV. An overview of the classes of available photosensitizers is provided and the properties governing photosensitizer uptake and circulation in serum are discussed. Current delivery systems, for example liposomal formulations as well as the use of the promising strategy of antibody targeted delivery as a strategy to improve PDT selectivity and efficiency for CNV treatment are described. A summary of the work using Verteporfin, tin ethyl purpurin and Lu-Tex--photosensitizers currently in clinical trials for CNV--is given.

Links

Publisher Full Text

Authors+Show Affiliations

Renno RZ
Retina Service, Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA.
Miller JW
No affiliation info available

MeSH

Choroidal NeovascularizationClinical Trials as TopicHumansLiposomesMetalloporphyrinsPhotochemotherapyPhotolysisPhotosensitizing AgentsPorphyrinsVerteporfin

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

11672876

Citation

Renno, R Z., and J W. Miller. "Photosensitizer Delivery for Photodynamic Therapy of Choroidal Neovascularization." Advanced Drug Delivery Reviews, vol. 52, no. 1, 2001, pp. 63-78.
Renno RZ, Miller JW. Photosensitizer delivery for photodynamic therapy of choroidal neovascularization. Adv Drug Deliv Rev. 2001;52(1):63-78.
Renno, R. Z., & Miller, J. W. (2001). Photosensitizer delivery for photodynamic therapy of choroidal neovascularization. Advanced Drug Delivery Reviews, 52(1), 63-78.
Renno RZ, Miller JW. Photosensitizer Delivery for Photodynamic Therapy of Choroidal Neovascularization. Adv Drug Deliv Rev. 2001 Oct 31;52(1):63-78. PubMed PMID: 11672876.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Photosensitizer delivery for photodynamic therapy of choroidal neovascularization. AU - Renno,R Z, AU - Miller,J W, PY - 2001/10/24/pubmed PY - 2002/1/5/medline PY - 2001/10/24/entrez SP - 63 EP - 78 JF - Advanced drug delivery reviews JO - Adv Drug Deliv Rev VL - 52 IS - 1 N2 - The present review examines the importance of improving photosensitizer delivery for choroidal neovascularization (CNV) in light of the clinical impact of photodynamic therapy (PDT) for CNV. An overview of the classes of available photosensitizers is provided and the properties governing photosensitizer uptake and circulation in serum are discussed. Current delivery systems, for example liposomal formulations as well as the use of the promising strategy of antibody targeted delivery as a strategy to improve PDT selectivity and efficiency for CNV treatment are described. A summary of the work using Verteporfin, tin ethyl purpurin and Lu-Tex--photosensitizers currently in clinical trials for CNV--is given. SN - 0169-409X UR - https://www.unboundmedicine.com/medline/citation/11672876/Photosensitizer_delivery_for_photodynamic_therapy_of_choroidal_neovascularization_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0169-409X(01)00195-8 DB - PRIME DP - Unbound Medicine ER -